ImVisioN Therapeutics Inc. is a private biotechnology company incorporated in Nevada, USA, with a heritage in Switzerland and Germany.

The Company is the pioneer in intralymphatic immunotherapy (ILIT ™), a proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. ILIT ™ is clinically proven and has been shown to be a safer, more efficacious and more convenient means of delivering allergy therapeutics. By applying another proprietary technology, Modular Antigen Transportation ™ (MAT ™), ImVisioN leverages the potential of ILIT ™ to develop drugs that use allergens safely for specific and highly effective antigen presentation. ImVisioN’s lead product is for the treatment of cat dander allergy and the Company has programs addressing birch pollen and house dust mite allergies. The Company’s proprietary technology platforms are applicable to further allergy targets, which may be addressed in the future.

latest news

• 06.02.2007
  Not for distribution in the United States
  
  ImVisioN Therapeutics strengthens patent position ...
• 03.03.2006
  Exclusive license from MannKind Corporation obtained...
• 23.05.2005
  Martin Steiner appointed as CEO...
• 03.05.2005
  BioVisioN AG sells its subsidiary ImVisioN GmbH to Nextech Venture, L.P....